DOW JONES25,409.36-357.28 -1.39%
S&P 5002,954.22-24.54 -0.82%
NASDAQ8,567.37+0.89 0.01%

Chardan Capital Upgrades Adverum Biotechnologies to Buy, Raises Price Target to $20

Chardan Capital analyst Gbola Amusa upgrades Adverum Biotechnologies (NASDAQ:ADVM) from Neutral to Buy and raises the price target from $10 to $20.

Benzinga · 02/10/2020 14:56

Chardan Capital analyst Gbola Amusa upgrades Adverum Biotechnologies (NASDAQ:ADVM) from Neutral to Buy and raises the price target from $10 to $20.